sacituzumab govitecan + pembrolizumab + carboplatin

This is an **investigational combination therapy** consisting of sacituzumab govitecan, pembrolizumab, and carboplatin, currently under clinical study primarily for the **first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations**. - **Sacituzumab govitecan** is a first-in-class antibody-drug conjugate targeting **trophoblast cell surface antigen 2 (Trop-2)**, delivering the cytotoxic payload SN-38. - **Pembrolizumab** is a monoclonal antibody **immune checkpoint inhibitor** targeting **programmed death-1 (PD-1)**, enhancing anti-tumor immune responses. - **Carboplatin** is a **platinum-based alkylating agent** that induces DNA crosslinking, leading to apoptosis in rapidly dividing cells. The rationale behind the combination is to leverage immune checkpoint inhibition and DNA-damaging chemotherapy with a targeted cytotoxic agent for synergistic antitumor activity. This regimen is being studied in EVOKE-02 (NCT05186974) and has shown encouraging efficacy with a manageable safety profile in early-phase results[1][2][4][5].

Other names

SG + pembrolizumab + carboplatinsacituzumab govitecan-hziy + pembrolizumab + carboplatinSG + CP + pembrolizumab